Targeting SYK activity in AML by pharmacological and genetic means induces differentiation and impairs growth in vitro, and it attenuates AML progression in vivo, an effect more dramatic in FLT3-ITD-positive AML [4–6]. This evidence concerns the gene SYK and acute myeloid leukemia.